The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer
JNCI: Journal of the National Cancer Institute · 2026
DOI: 10.1093/jnci/djaf236 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2026. Verfasst von Margaux Wooster und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, 10032, United States. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins p21(ras), Lung Neoplasms, Patient Selection. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ASCO Young Investigator, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
20% of patients with cancer are estimated to be ineligible for phase III trials because of restrictive eligibility criteria. Ineligibility rates for earlier phase trials are even greater. In response, several groups, including the US Food and Drug Administration, have advocated for more inclusive study designs. We examined Kirsten rat sarcoma virus (KRAS) G12C inhibitor trials to determine if inclusivity has shifted in the development of molecularly targeted therapies.
Methods
We evaluated phase I-III studies of KRAS G12C inhibitors in non–small cell lung cancer (NSCLC) by applying criteria from 15 US trials to a multi-institutional real-world cohort of patients with metastatic NSCLC and universal KRAS testing (n = 2383). Eligibility analysis, multivariate logistic regression for ineligibility, and a Cox proportional hazards model were used on patients with KRAS G12C–mutated NSCLC (n = 185) to compare trial enrollment and overall survival under various eligibility modifications.
Results
Of patients with metastatic KRAS G12C-mutated NSCLC, 60%-70% were ineligible for any KRAS inhibitor clinical trial, including studies aiming to establish first-line standard of care. Eligibility criteria remained unchanged from phase I to phase III. Performance status, renal function, and active brain metastases were the main causes of trial ineligibility. Liberalizing criteria for renal function and brain metastases increased enrollment by 25% without affecting overall survival (P = .49), whereas allowing worse performance status reduced study effect sizes (P = .001 in second-line and P = .04 in first-line).
Conclusions
Most patients with metastatic KRAS G12C-mutated NSCLC are excluded from trials. There is substantial potential to refine trial entry criteria to better balance generalizability, safety, speed, and success.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, 10032, United States.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, United States.
- Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, 10021, United States.
- Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, United States.
- Department of Biostatistics, Columbia University Irving Medical Center, New York, NY, 10032, United States.
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, 10032, United States.
ORCID-Profile: Margaux Wooster, Michael May, Xin Ma, Stephanie Bogdan, Catherine A Shu, Brian S Henick, Anjali Saqi, Mahesh Mansukhani, Dawn L Hershman, Kathryn C Arbour, Benjamin O Herzberg
Förderung
- ASCO Young Investigator
- NCI NIH HHS
- NIH HHS
- NIH
Zitieren
APA
Wooster, M., May, M., Agrawal, P., Lee, J., May, B., Ma, X., Bogdan, S., Shu, C. A., Henick, B. S., Saqi, A., Mansukhani, M., Riely, G., Hershman, D. L., Garcia, C., Arbour, K. C., & Herzberg, B. O. (2026). The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf236
Vancouver
Wooster M, May M, Agrawal P, Lee J, May B, Ma X, et al. The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djaf236
BibTeX
@article{Wooster2026,
author = {Wooster, Margaux and May, Michael and Agrawal, Prashasti and Lee, Jonathan and May, Benjamin and Ma, Xin and Bogdan, Stephanie and Shu, Catherine A and Henick, Brian S and Saqi, Anjali and Mansukhani, Mahesh and Riely, Gregory and Hershman, Dawn L and Garcia, Christine and Arbour, Kathryn C and Herzberg, Benjamin O},
title = {The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2026},
doi = {10.1093/jnci/djaf236}
}
EUVIMED